Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
EW · NYSE · Health Care Equipment
Edwards Lifesciences (EW) · oqro.io/stocks/EW · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Edwards Lifesciences was filed in the last 90 days. The latest on record was on May 6, 2024.
Since 2006, Edwards Lifesciences insiders reported 12 open-market purchases and 2,686 sales on Forms 4 and 5, with purchases in 7 different years, most recently 2024.
In the last 90 days, 7 insiders of Edwards Lifesciences (EW) reported 11 open-market sales worth $10.9M in total on SEC Form 4. The largest seller by value was Donald E Jr Bobo, with $5.04M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 2 trades in Edwards Lifesciences (EW) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Sen. Alan Armstrong, Rep. Josh Gottheimer (NJ05).
Edwards Lifesciences's next results are expected on Feb 8, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$105.23−0.20 (−0.19%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
+25.2% (+$21.19) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $84.04 on Nov 18, 2025 to $105.23 on Nov 18, 2026 (+25.2%). Disclosed in this range: 23 insider trades, 32 pre-arranged insider sales, 2 Congress trades, and 61 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Equipment company based in Irvine, California.
Last 12 months
+25.2%
Market value
$60.5B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 9.38M shares sold short (1.6% of shares outstanding), +0.5% vs the previous count, 2.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$1.72B
+10.5% vs the same quarter a year earlier
Free cash flow, last 12 months
$1.42B
This quarter $507M, a year earlier $516M
Net cash
$2.51B
Debt $599M, cash $3.11B, at Sep 30, 2026
Net income, last 12 months
$1.02B
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 4, 2026.
Revenue, fiscal 2025
$6.07B
+11.5% vs the year before
Net income, fiscal 2025
$1.07B
As reported in the annual filing
Shares outstanding
575M
As of Oct 31, 2026
In fiscal 2025 the company spent $893M buying back its own shares. Cash actually paid, from its cash-flow statement.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Daniel J. Lippis (Officer) plans to sell ~$194K of Edwards Lifesciences
Against the S&P 500 over the year
Since Nov 17, 2025, EW is up 24.2% and the index fund is up 9.7%: 14 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much EW moves
Beta 0.5 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Edwards Lifesciences over the 12 months to Nov 19, 2026: 10 FDA records and 5 executive contributions.
Written by software from the filings listed below · Nov 13, 2026
3 more points, with the facts they come from, are in OQRO Pro.
Sign up freeInsiders of Edwards Lifesciences reported 12 open-market purchases and 2,686 sales since 2006; purchases in 7 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $28.8M45×45 trades |
| 2025 | — | $17.3M41×41 trades |
| 2024 | $50K1×1 trade | $37.8M61×61 trades |
| 2023 | — | $61.2M79×79 trades |
| 2022 | — | $74.4M115×115 trades |
| 2021 | $168K1×1 trade | $106M96×96 trades |
| 2020 | — | $129M152×152 trades |
| 2019 | — | $131M149×149 trades |
| 2018 | — | $124M140×140 trades |
| 2017 | $270K1×1 trade | $93.3M73×73 trades |
| 2016 | $1.83M4×4 trades | $107M94×94 trades |
| 2015 | — | $85.1M78×78 trades |
| 2014 | — | $96.5M75×75 trades |
| 2013 | $383K3×3 trades | $43.3M46×46 trades |
| 2012 | — | $151M153×153 trades |
| 2011 | $10K1×1 trade | $88.3M82×82 trades |
| 2010 | $57K1×1 trade | $83.3M77×77 trades |
| 2009 | — | $45.6M60×60 trades |
| 2008 | — | $20.7M235×235 trades |
| 2007 | — | $23.9M680×680 trades |
| 2006 | — | $10.7M155×155 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Vanguard Capital Management
13G · passive · Crossed 5% · 43.5M shares · filed Apr 29, 2026
BlackRock, Inc.
13G · passive · Amended · 44.3M shares · filed Oct 17, 2025
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Last results
Nov 4, 2026
Within the 30 days after it, until Dec 4, 2026
Next results, expected
Feb 8, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Edwards Lifesciences's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Edwards Lifesciences's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Latest annual report filed Feb 25, 2026, compared with the one filed Feb 28, 2025. Read the filing
Please see Note 20 to our Consolidated Financial Statements in this Annual Report for a description of our legal proceedings, which is incorporated by reference herein. We are subject to various environmental laws and regulations both within and outside of the United States. Our operations, like those of other medical device companies, involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 25, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Short sale volume: 44.5% of the volume reported to FINRA over the last 20 trading days was marked short, close to its 1-year average of 44.1%. FINRA daily files, to Nov 18, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Off-exchange trading: 45.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (29.7% on ATS, 15.3% with other brokers), close to its 26-week average of 43.8%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: INTELLIGENT CROSS LLC (14.4%), UBS ATS (11.8%), SIGMA X2 (9.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, 8:24-cv-02221Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). Coverage of court records is not complete, and shareholder derivative suits are not included.
8 approvals or clearances and 2 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
People read Edwards Lifesciences's Wikipedia article about 60 times a day over the last week, fewer than the 79 on a usual day of the three months before.
May 14, 2026Busiest day: 170 views on May 21, 2026Nov 18, 2026
Views of the article Edwards Lifesciences, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
18 certified in FY2026 Q3, vs 29 a year earlier. 18 positions in total, median offered wage $123K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Attention
Things to keep in mind
Records